Inferra AIResearch Tools

Inferra AI / Company / PFE

Pfizer

PFE · Health Care

Last earnings Aug 4, 2026  ·  Next earnings Nov 3, 2026

Key results

Revenuequarter

$14.7 Billion

Revenues of $14.7 Billion,

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

EPSquarter

$0.51

Diluted EPS of $0.51, and Adjusted (2)

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

REVENUES ($ in millions) Second-Quarter Six Months 2025 2024 % Change 2025 2024 % Change Total Oper.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Second-Quarter 2024) Second-quarter 2025 revenues totaled $14.7 billion, an increase of $1.4 billion, or 10%, compared to the prior-year quarter, reflecting an operational increase of $1.3 billion, or 10%, as well as a favorable impact of foreign exchange of $22 million.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Growthquarter

up 21%

Second-quarter 2025 operational revenue growth was driven primarily by Vyndaqel family (Vyndaqel, Vyndamax, Vynmac) globally, up 21% operationally, driven largely by strong demand with continuing uptake in patient diagnosis primarily in the U.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

revenues from both a favorable net sales adjustment and higher demand for the maternal indication that more than offset - 4 - lower vaccination rates for the older adult indication following an updated Advisory Committee on Immunization Practices (ACIP) recommendation as well as launch uptake for both the adult and maternal indications in certain international markets and Lorbrena globally, up 48% operationally, driven primarily by increased patient share in the first-line ALK-positive metastatic non-small cell lung cancer (ALK+ mNSCLC) treatment setting in the U.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

mainly due to the impact of higher manufacturer discounts resulting from the IRA Medicare Part D Redesign partially offset primarily by lower revenues for Ibrance globally, down 8% operationally, driven primarily by lower net price in the U.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

revenues increased by 0.9 percentage points compared to the prior-year quarter, driven primarily by the non-recurrence of a favorable revision to accrued royalties recorded in the second quarter of 2024, partially offset by lower amortization from the step-up of acquired inventory.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

AI analysis

Q2 2025 · reported Aug 5, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Revenue · Q2 2025
$14.7B
EX-99 · Aug 5, 2025
EPS · Q2 2025
$0.51
EX-99 · Aug 5, 2025

Headline figures

MetricQ2 2025Prior qtrYear ago
Revenue$14.7 Billion——
EPS$0.51——
Growthup 21%——

EX-99 · Aug 5, 2025

Guidance · company-stated

Direction: Raised

EPS

“htm EX-99 Document Exhibit 99 g Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance Strengthened Commercial Execution Driving Topline Growth Continued Progress Across R D Pipeline Expanded Programs On Track to Deliver Net Cost Savings Targets NEW YORK, Tuesday, August 5, 2025 Pfizer Inc.”

Revenue

“Global Biopharmaceuticals Business (Biopharma) $ 14,305 $ 12,991 10% 10% $ 27,746 $ 27,595 1% 1% Pfizer CentreOne (PC1) 328 278 18% 18% 585 535 9% 10% Pfizer Ignite 20 15 38% 38% 37 32 16% 16% TOTAL REVENUES $ 14,653 $ 13,283 10% 10% $ 28,367 $ 28,162 1% 2% - 2 - 2025 FINANCIAL GUIDANCE (1) Reaffirms full-year 2025 Revenue guidance and raises Adjusted (2) diluted EPS guidance (1) by $0.10 at the midpoint to a range of $2.90 to $3.10.”

Classified from the release's primary full-year outlook statement.

Next earningsNov 3, 2026Verified from the company’s own announcement

Capital allocation

Dividend$4.9B

Returning capital directly to shareholders through $4.9 billion of cash dividends, or $0.86 per share of common stock.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

(NYSE PFE) reported financial results for the second quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising guidance (1) for Adjusted (2) diluted EPS

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Direction: Raised

EPS: “htm EX-99 Document Exhibit 99 g Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance Strengthened Commercial Execution Driving Topline Growth Continued Progress Across R D Pipeline Expanded Programs On Track to Deliver Net Cost Savings Targets NEW YORK, Tuesday, August 5, 2025 Pfizer Inc.”

Revenue: “Global Biopharmaceuticals Business (Biopharma) $ 14,305 $ 12,991 10% 10% $ 27,746 $ 27,595 1% 1% Pfizer CentreOne (PC1) 328 278 18% 18% 585 535 9% 10% Pfizer Ignite 20 15 38% 38% 37 32 16% 16% TOTAL REVENUES $ 14,653 $ 13,283 10% 10% $ 28,367 $ 28,162 1% 2% - 2 - 2025 FINANCIAL GUIDANCE (1) Reaffirms full-year 2025 Revenue guidance and raises Adjusted (2) diluted EPS guidance (1) by $0.10 at the midpoint to a range of $2.90 to $3.10.”

EPS — Raised (“Raises”)
“htm EX-99 Document Exhibit 99 g Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance Strengthened Commercial Execution Driving Topline Growth Continued Progress Across R D Pipeline Expanded Programs On Track to Deliver Net Cost Savings Targets NEW YORK, Tuesday, August 5, 2025 Pfizer Inc.”

Revenue — Raised (“raising”)
“(NYSE PFE) reported financial results for the second quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising guidance (1) for Adjusted (2) diluted EPS.”

EPS — Raised (“raised”)
“We raised our full-year 2025 Adjusted diluted EPS guidance, demonstrating confidence in our ability to execute against our strategic priorities and deliver strong results for shareholders.”

Revenue — Raised (“raises”)
“Global Biopharmaceuticals Business (Biopharma) $ 14,305 $ 12,991 10% 10% $ 27,746 $ 27,595 1% 1% Pfizer CentreOne (PC1) 328 278 18% 18% 585 535 9% 10% Pfizer Ignite 20 15 38% 38% 37 32 16% 16% TOTAL REVENUES $ 14,653 $ 13,283 10% 10% $ 28,367 $ 28,162 1% 2% - 2 - 2025 FINANCIAL GUIDANCE (1) Reaffirms full-year 2025 Revenue guidance and raises Adjusted (2) diluted EPS guidance (1) by $0.10 at the midpoint to a range of $2.90 to $3.10.”

Classified from the release's primary full-year outlook statement.

Capital allocation

Returning capital directly to shareholders through $4.9 billion of cash dividends, or $0.86 per share of common stock.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

- 3 - No share repurchases have been completed to date in 2025.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

As of August 5, 2025, Pfizer s remaining share repurchase authorization is $3.3 billion.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Current financial guidance does not anticipate any share repurchases in 2025.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

This includes maintaining the flexibility to deploy capital towards potential value-creating business development transactions and the potential to return capital to shareholders through share repurchases.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Guidance for Adjusted (2) diluted EPS assumes diluted weighted-average shares outstanding of approximately 5.72 billion shares, and assumes no share repurchases in 2025.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Strategy & priorities

David Denton, CFO and EVP of Pfizer Our robust second-quarter Revenue and EPS performance demonstrates our continued focus on commercial execution and operational efficiency.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

We raised our full-year 2025 Adjusted diluted EPS guidance, demonstrating confidence in our ability to execute against our strategic priorities and deliver strong results for shareholders.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

The updated 2025 Adjusted (2) diluted EPS guidance takes into consideration our strong year-to-date performance, continued confidence in our business, a favorable impact from foreign exchange, progress with ongoing cost improvement initiatives, and improvement in our effective tax rate.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

The company expects to continue to de-lever in a prudent manner in order to maintain a balanced capital allocation strategy.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

(4) On track to deliver approximately $7.7 billion in anticipated overall savings (approximately $7.2 billion of net cost savings) from previously announced cost improvement initiatives Approximately $4.5 billion of overall net cost savings from Pfizer s ongoing cost realignment program are expected to be achieved by the end of 2025.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Risks & headwinds

The company s guidance absorbs the impact of the currently imposed tariffs from China, Canada, and Mexico, as well as potential price changes this year based on the letter received on July 31, 2025 from President Trump.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

generally accepted accounting principles (GAAP) Reported financial measures (other than revenues) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP Reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, certain acquisition-related expenses, gains and losses from equity securities, actuarial gains and losses from pension and postretirement plan remeasurements, potential future asset impairments and pending litigation without unreasonable effort.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

T he company s guidance absorbs the impact of the currently imposed tariffs from China, Canada, and Mexico, as well as potential price changes this year based on the letter received on July 31, 2025 from President Trump.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions and we cannot assure you that any outcome expressed in these forward-looking statements will be realized in whole or in part.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Pfizer s financial guidance is based on estimates and assumptions that are subject to significant uncertainties.

SEC original ↗Pfizer — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Legal Proceedings 52 Item 1A.

SEC original ↗Pfizer — 10-Q Quarterly report10-QAug 4, 2026

Documents

Earnings deck slides

3 decks with slide view

Pfizer — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Slide history — recurring slides by stated title

Slides are matched across this company’s decks by their stated title only; a title listed here appeared in more than one held deck.

PFIZER INC. — Oct 21, 2026 · slide 9 · Oct 21, 2026 · slide 9

PFIZER INC. REVENUES — Oct 21, 2026 · slide 2 · Oct 21, 2026 · slide 2

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

69 documents

Earnings releases

22 documents

Presentations

4 documents

Transcripts

0 documents

No transcripts for Pfizer are held in this edition of the library.

Mentioned by

13 companies

Other tracked companies whose held documents mention Pfizer by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.